This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Sanofi, China.
Reference
Zhang L, et al. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective. Clinical Therapeutics : 20 Nov 2018. Available from: URL: http://doi.org/10.1016/j.clinthera.2018.10.018
Rights and permissions
About this article
Cite this article
Clopidogrel vs aspirin in acute coronary syndrome in China. PharmacoEcon Outcomes News 818, 12 (2018). https://doi.org/10.1007/s40274-018-5510-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5510-1